KHPG(SZ:002773)2023-04-27 16:00Financial Performance - Total revenue for Q1 2023 was CNY 88,483.86 million, a decrease of 1.16% compared to CNY 89,521.23 million in Q1 2022[3] - The revenue from traditional Chinese medicine reached CNY 33,680.52 million, representing a 10.72% increase year-over-year[3] - The revenue from chemical drugs decreased by 17.06% to CNY 20,398.74 million compared to CNY 24,594.54 million in the same period last year[3] - The company reported a net profit of CNY 12,799,852.71 from non-operating income and expenses after tax adjustments[4] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.30, down from CNY 0.32 in the previous year[14] - Net profit attributable to shareholders of the listed company was ¥279,331,041.04, down 6.03% from ¥297,240,188.25 year-on-year[54] - The net profit after deducting non-recurring gains and losses was ¥266,531,188.33, a decrease of 4.63% from ¥279,472,064.65 year-on-year[54] Cash Flow and Assets - Cash and cash equivalents decreased by 40.38% to CNY 2,137,765,906.48 from CNY 3,585,368,804.77 at the beginning of the year[5] - The net cash flow from operating activities is CNY 187,686,073.46, down from CNY 288,758,045.97 in the previous period[31] - The net cash flow from operating activities decreased by 35.00%, amounting to ¥187,686,073.46 compared to ¥288,758,045.97 in the previous year[54] - The cash and cash equivalents at the end of the period amount to CNY 2,122,513,089.46, compared to CNY 1,914,464,515.05 in the previous period[32] - The company’s total assets at the end of the period are CNY 7,897,627,039.38, an increase from CNY 7,720,729,941.31[28] - The total assets at the end of the reporting period were ¥7,897,627,039.38, reflecting a 2.29% increase from ¥7,720,729,941.31 at the end of the previous year[54] Liabilities and Equity - The company's total liabilities amount to CNY 713,323,012.95, a decrease from CNY 813,851,345.77 in the previous period[28] - The total non-current liabilities are CNY 106,638,444.55, down from CNY 120,191,379.00[28] - The equity attributable to shareholders of the listed company increased by 4.05% to ¥7,181,367,694.78 from ¥6,901,806,830.70[54] - The total equity attributable to the parent company is CNY 7,181,367,694.78, up from CNY 6,901,806,830.70 in the previous period[28] Research and Development - R&D expenses for Q1 2023 were CNY 68,663,415.81, up from CNY 54,727,925.74 in Q1 2022, reflecting a focus on innovation[12] Government Support - The company received government subsidies amounting to CNY 16,229,962.73, contributing to its financial performance[4] Shareholder Information - The total number of common shareholders at the end of the reporting period is 47,320, with the largest shareholder holding 31.76% of shares[24] Other Financial Metrics - The weighted average return on net assets was 3.97%, down from 4.76% in the previous year[54] Changes in Receivables and Payables - Accounts receivable rose by 46.57% to CNY 219,305,112.58, indicating an increase in outstanding payments[5] - Other receivables increased by 71.58% compared to the beginning of the period, mainly due to an increase in the reserve fund during the reporting period[57] - Prepayments increased by 209.48% compared to the beginning of the period, primarily due to an increase in sales discount refunds during the reporting period[57] - Employee compensation payable decreased by 61.82% compared to the beginning of the period, mainly due to the payment of last year's year-end bonuses during the reporting period[57] - Taxes payable increased by 90.66% compared to the beginning of the period, primarily due to an increase in corporate income tax payable during the reporting period[57] - Other payables increased by 66.56% compared to the beginning of the period, mainly due to an increase in payable expense reimbursements during the reporting period[57] - Other current liabilities decreased by 49.35% compared to the beginning of the period, mainly due to a decrease in estimated discounts during the reporting period[57] - Financial expenses decreased by 61.27% compared to the beginning of the period, mainly due to an increase in interest income during the reporting period[57] Market Expansion - The company received orphan drug designation from the FDA for its product KH617, indicating potential for future market expansion[42]